速报，国产测序仪公司刚刚完成2.8亿元C+轮融资，加速全球化布局

Core Viewpoint - Zhenmai Bio has successfully completed a C+ round financing of 280 million yuan, aiming to enhance its commercialization ecosystem and global expansion strategy, thereby accelerating domestic substitution and technological breakthroughs abroad [1][3]. Financing and Strategic Goals - The financing round was led by multiple investors including Shengxiang Bio, Jinyu Medical, and others, which will provide sufficient momentum for market consolidation, capacity expansion, and compliance layout [1]. - The funds will support Zhenmai Bio's strategic goals of commercial ecosystem construction and global expansion [1]. Product Development and Achievements - Zhenmai Bio has launched two flagship products: the SURFSeq 5000, which has the highest global throughput of 2.2 Tb/run, and the SURFSeq Q, which boasts a daily output of 9 Tb, both receiving high recognition from users [2]. - The company has received regulatory approval for two significant medical devices, marking a milestone in domestic high-throughput sequencing technology [2]. Market Expansion and Partnerships - Zhenmai Bio's global business has expanded to over 50 countries and regions, with nearly 500 substantial partnerships, including top research institutions and clinical medical organizations [3]. - The company aims to strengthen its industry advantages and accelerate its position as a global leader in gene sequencing and life omics [3]. Leadership and Investor Insights - The chairman of Zhenmai Bio expressed gratitude for the support from shareholders, emphasizing the strategic resonance between capital, innovation, and industry chains [4]. - Investors highlighted Zhenmai Bio's strong capabilities in sequencing technology and its potential for international breakthroughs, indicating a commitment to deepening collaboration in precision medical technology [5][6].